Detailed company information
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
Last Updated: Sep 2026
Earnings Transcript for 2027 - Q1Released: Aug 06, 2026
Earnings Transcript for 2026 - Q4Released: May 14, 2026
Earnings Transcript for 2026 - Q3Released: Feb 05, 2026
Earnings Transcript for 2026 - Q2Released: Nov 06, 2025
Earnings Transcript for 2026 - Q1Released: Aug 08, 2025
Earnings Transcript for 2025 - Q4Released: May 11, 2025
Earnings Transcript for 2025 - Q3Released: Feb 06, 2025
Earnings Transcript for 2025 - Q2Released: Nov 09, 2024
Earnings Transcript for 2025 - Q1Released: Aug 08, 2024
Earnings Transcript for 2024 - Q4Released: May 15, 2024
Earnings Transcript for 2024 - Q3Released: Feb 08, 2024
Earnings Transcript for 2024 - Q2Released: Nov 02, 2023
Earnings Transcript for 2024 - Q1Released: Aug 05, 2023
Earnings Transcript for 2023 - Q4Released: May 06, 2023
Earnings Transcript for 2023 - Q3Released: Feb 02, 2023
Earnings Transcript for 2023 - Q2Released: Nov 06, 2022
Earnings Transcript for 2023 - Q1Released: Aug 07, 2022
Earnings Transcript for 2022 - Q4Released: May 06, 2022
Earnings Transcript for 2022 - Q3Released: Feb 03, 2022
Earnings Transcript for 2022 - Q2Released: Nov 04, 2021
Earnings Transcript for 2022 - Q1Released: Aug 07, 2021
Earnings Transcript for 2021 - Q4Released: May 08, 2021
Earnings Transcript for 2021 - Q3Released: Feb 04, 2021
Earnings Transcript for 2021 - Q2Released: Nov 05, 2020
ANIP ANI Pharmaceuticals, Inc.
PAHC Phibro Animal Health Corporation
COLL Collegium Pharmaceutical, Inc.
AMPH Amphastar Pharmaceuticals, Inc.
PCRX Pacira BioSciences, Inc.
SUPN Supernus Pharmaceuticals, Inc.
PRGO Perrigo Company plc
COTY Coty Inc.
PG The Procter & Gamble Company
GLAXO GlaxoSmithkline Pharmaceuticals Ltd.
SPB Spectrum Brands Holdings, Inc.
CL Colgate-Palmolive Company
This discussion explores the primary factors behind Prestige Consumer Healthcare's Q4 revenue shortfalls, focusing on the impact of supply issues and international shipping disruptions.
Read post
Dafinchi